| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
AbCellera Biologics Inc.$6.8
-0.39 (-5.35%)
D 31Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.87 B
EPS
-0.48
P/E Ratio
-12.78 $
Value Trade
40.72 M
SEC Financials
Q1 2026Dilution Risk
Revenue
8.31 M
R&D Expenses
46.66 M
Operating CF
-33.52 M
Total Assets
1.31 B
Total Liabilities
369.03 M
Equity
938.08 M
D/E Ratio
12,345
22.07 %
Week
28.4 %
1 Month
64.56 %
3 Month
52.05 %
6 Month
-83.34 %
5 Year
-91.48 %
All Time
Cash Data
Cash Position
504.73 M
Monthly Burn
11.17 M
Runway
43.4 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
7.28 M
52 Week Range
2.27 - 6.79
% held by Insiders
23.04 %
% held by Institutions
41.56 %
Enterprise Value
1.48 B
Total Shares
299.46 M
Short %
19.11 %
Float Shares
208.73 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AbCellera Biologics Inc.
68Total events
0Upcoming
18Tier-1 (high impact)
2016 – 2026Coverage
Event history 68
Q3 2026
◆Topline ReadoutABCL635Clinical Data
Top-line clinical results for both Phase 1 and Phase 2 anticipated
vasomotor symptoms due to menopausesource ↗
May 12, 2026
▲Interim AnalysisABCL635Trial
Positive interim Phase 1 data for ABCL635 SAD part
moderate-to-severe vasomotor symptoms (VMS) associated with menopausesource ↗
May 2026
◆Oral PresentationPresentation
AbCellera to present at investor conferences in May and June 2026
Mar 2026
◆Oral PresentationPresentation
AbCellera to present at investor conferences in March and April 2026
Jan 13, 2026
▲First Patient DosedABCL635Trial
First patients dosed in Phase 2 portion of Phase 1/2 trial of ABCL635
vasomotor symptoms due to menopausesource ↗
2026
●Development Candidate NominationPreclinical
Select at least one additional development candidate
2026
▲Trial InitiationABCL635Trial
Phase 2 study initiated
moderate-to-severe vasomotor symptoms (VMS) associated with menopausesource ↗
Drug Pipeline Intelligence
D31
Pipeline Score $83M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 39%
Micro Cap (rank 557 of 911)
Percentile RankAbCellera Biologics Inc. faces pipeline headwinds (31/100), with $208M risk-adjusted pipeline value, led by ABCL575 in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABCL575 Monoclonal antibody | Healthy Volunteers | Phase 1 | NCT07108894 | 13% | $126M | ACTIVE NOT_RECRUITING | 40 | SLOW | C (53) | Apr 1, 2027 | LOW_RISK | MEDIUM Jun 16, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ABCL635 | vasomotor symptoms associated with menopause | Phase 1 | 2026-05-12 | robust NK3R target engagement; well-tolerated in healthy volunteers; doses ranging from 30 mg to 900 mg; multiple once monthly doses ranging from 300 mg to 600 mg Read More | AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 Read More | |
ABCL635 | vasomotor symptoms associated with menopause | Phase 1 | 2026-05-12 | robust NK3R target engagement; well-tolerated in healthy volunteers; doses ranging from 30 mg to 900 mg; multiple once monthly doses ranging from 300 mg to 600 mg Read More | AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 Read More | |
ABCL635 | vasomotor symptoms associated with menopause | Phase 1 | 2026-05-12 | robust NK3R target engagement; well-tolerated in healthy volunteers; doses ranging from 30 mg to 900 mg; multiple once monthly doses ranging from 300 mg to 600 mg Read More | AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ABCL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ABCL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ABCL▼ -5.7%on this news· ran to -22% by day 3
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
AbCellera reported positive interim results from the Phase 1 clinical trial of ABCL635, an antibody targeting NK3R for treating vasomotor symptoms associated with menopause. The data indicated robust target engagement and good tolerability among participants. The company plans to advance ABCL635 into Phase 2 trials, with results expected in Q3 2026. Additionally, AbCellera maintains a strong financial position with significant liquidity.
Read more →ABCL▲ +8.7%on this newsshared move
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
AbCellera Biologics Inc. announced its participation in upcoming investor conferences scheduled for May and June 2026. The company will provide live audio webcasts of its presentations, which will also be available for replay afterward. AbCellera specializes in developing first-in-class antibody-based therapies across various medical fields.
Read more →ABCLAbCellera Reports Full Year 2025 Business Results
AbCellera reported strong financial results for the full year 2025, highlighting its transition to a clinical-stage biotech company. The company ended the year with about $700 million in liquidity and advanced 19 molecules into clinical stages. The CEO emphasized the potential of their growing pipeline and upcoming clinical readouts.
Read more →ABCL▼ -6.1%on this news
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
AbCellera has announced its participation in upcoming investor conferences scheduled for March and April 2026. The company will provide live audio webcasts of its presentations, which will also be available for replay afterward. AbCellera specializes in developing antibody-based therapies across various therapeutic areas.
Read more →ABCL▼ -8.6%on this news
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
AbCellera Biologics Inc. will announce its full year 2025 financial results on February 24, 2026. The announcement will be followed by an earnings conference call at 2:00 p.m. PT. Investors can access a live audio webcast of the call on the company's Investor Relations website, with a replay available afterward.
Read more →ABCL▼ -5.5%on this news
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
AbCellera has initiated the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635, a potential first-in-class treatment for vasomotor symptoms related to menopause. Following a positive interim review from Phase 1, the trial will assess the drug's efficacy in 80 postmenopausal women. Results are anticipated in Q3 2026.
Read more →ABCL▼ -7.3%on this news
AbCellera Reports Full Year 2022 Business Results 02/21/2023 Total revenue of $485 million, compared to $375 million in FY 2021 Total cumulative partnered program starts of 101, with 23 new starts in the yea
AbCellera has reported strong financial results for the year 2022, with total revenue reaching $485 million, a significant increase compared to $375 million in 2021. The company marked a 29% rise in partnered program starts and advanced a total of eight molecules into clinical trials. Despite the positive growth, AbCellera faced a net loss of $29.9 million in the fourth quarter, partly due to issues with royalties following the suspension of bebtelovimab's EUA. Overall, AbCellera sees itself at an inflection point with an expectation to deliver more clinical candidates in the future.
Read more →ABCLAbCellera Reports Q3 2022 Business Results 11/08/2022 Total revenue of $101 million, compared to $6 million in Q3 2021 Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021
AbCellera Reports Q3 2022 Business Results VANCOUVER, British Columbia, November 8, 2022 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2022.
Read more →ABCL▼ -5.5%on this news· ran to +16% by day 3
AbCellera Q2 2022 BUSINESS UPDATE AUGUST 9, 2022 COPYRIGHT ABCELLERA DISCLAIMER Q2 2022 BUSINESS UPDATE This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisi
DISCLAIMER Q2 2022 BUSINESS UPDATE This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and
Read more →ABCLLilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options 06/29/2022 Bebtelovimab continues to
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options Bebtelovimab continues to maintain neutralization activity against all known variants of interest and concer
Read more →ABCLAbCellera Reports Q1 2022 Business Results 05/10/2022 Total revenue of $317 million, compared to $203 million in Q1 2021 Six program starts in the quarter bringing cumulative total to 84, up 56% from Q1 2021
AbCellera Reports Q1 2022 Business Results VANCOUVER, British Columbia, May 10, 2022 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2022. All
Read more →ABCLAbCellera Reports Full Year 2021 Business Results 02/24/2022 Total revenue of $375 million, up from $233 million in 2020, and liquidity of over $720 million Total cumulative program starts of 78, with 26 new
AbCellera Reports Full Year 2021 Business Results VANCOUVER, British Columbia, February 24, 2022 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for full year 2021. Al
Read more →ABCLAbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 2/11/2022 Bebtelovimab (LY-CoV1404) neutralizes Omicron, including th
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 Models of bebtelovimab Fabs bound to SARS-CoV-2 spike protein mapped with key mutations from the Omicron variant of concern. Left: Side view
Read more →ABCL▲ +7.8%on this news
AbCellera Announces Changes to Its Board of Directors 12/7/2021 VANCOUVER, British Columbia
AbCellera Announces Changes to Its Board of Directors VANCOUVER, British Columbia, December 7, 2021 - AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with
Read more →ABCLAbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer 12/02/2021 VANCOUVER, British Columbia
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer VANCOUVER, British Columbia, December 2, 2021 - AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appoint
Read more →ABCLAbCellera Reports Q3 2021 Business Results 11/09/2021 Total revenue of $6 million, compared to $9 million in Q3 2020 Nine program starts in the quarter bringing cumulative total to 69, up 35% from Q3 2020 Ne
AbCellera Reports Q3 2021 Business Results VANCOUVER, British Columbia, November 9, 2021 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2021.
Read more →ABCLLilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19 11/02/2021 VANCOUVER, B
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19 VANCOUVER, British Columbia - AbCellera (Nasdaq: ABCL) today announced an additional purchase b
Read more →ABCLLilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 09/21/2021 Bamlanivimab and etesevimab administered together neutraliz
Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 VANCOUVER, British Columbia - AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have ent
Read more →ABCL▼ -6.6%on this news
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets 09/13/2021 Acquisition expands AbCellera's existing capabilities to unlock difficult-to-drug transme
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets Acquisition expands AbCellera's existing capabilities to unlock difficult-to-drug transmembrane proteins for antibody discovery programs VANCOUVER, British Columbia & BOST
Read more →ABCLAbCellera Reports Q2 2021 Business Results 08/12/2021 Total revenue of $28 million, up from $11 million in Q2 2020 Total programs under contract of 138, up 82% from Q2 2020 Net loss of ($0.01) per share (bas
AbCellera Reports Q2 2021 Business Results VANCOUVER, British Columbia, August 12, 2021 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the second quarter of 2021.
Read more →ABCLAbCellera Appoints Neil Berkley as Chief Business Officer 07/13/2021 VANCOUVER, British Columbia- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibo
AbCellera Appoints Neil Berkley as Chief Business Officer VANCOUVER, British Columbia- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Busines
Read more →ABCLa AbCellera Reports Q1 2021 Business Results Total revenue of $203 million, up from $5 million in Q1 2020 Total programs under contract of 119, up 63% year-over-year EPS of $0.43 (basic) and $0.37 (diluted) compared to $
AbCellera Reports Q1 2021 Business Results VANCOUVER, British Columbia, May 13, 2021 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2021. "O
Read more →ABCLAbCellera Reports Q1 2021 Business Results Total revenue of $203 million, up from $5 million in Q1 2020 Total programs under contract of 119, up 63% year-over-year EPS of $0.43 (basic) and $0.37 (diluted) compared to $0.
AbCellera Reports Q1 2021 Business Results VANCOUVER, British Columbia, May 13, 2021 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2021. "O
Read more →ABCLAbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera s entire technology stack, i
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera s entire technology stack, including the Trianni Mouse and the OrthoMab bispecific pla
Read more →ABCLAbCellera Reports Full Year 2020 Business Results Total revenue of $233 million 1 in 2020, up 1,908% year-over-year Total revenue from research fees of $20 million, up 71% year-over-year Total programs under contract of
AbCellera Reports Full Year 2020 Business Results VANCOUVER, British Columbia - March 29, 2021 - AbCellera (NASDAQ: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the full year 2020 wi
Read more →ABCLAbCellera Announces Expanded Research Collaboration with Teva
VANCOUVER, British Columbia, June 13, 2017 (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Teva Pharmaceutical Industries, Ltd. Under the agreement, which builds on a successful first partnership completed in 2
Read more →ABCLAbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research
VANCOUVER, British Columbia, June 06, 2017 (GLOBE NEWSWIRE) -- AbCellera has entered into a collaborative research effort with Sanofi Pasteur, a global leader in the development and sale of vaccines for seasonal influenza. The project will use AbCellera’s single-cell screening pl
Read more →ABCLAbCellera Receives Grant to Help Fight Tuberculosis
AbCellera received a grant from the Bill & Melinda Gates Foundation to discover antibodies against Mycobacterium tuberculosis. VANCOUVER, British Columbia, Jan. 19, 2017 (GLOBE NEWSWIRE) -- AbCellera today announced a grant from the Bill & Melinda Gates Foundation to discover mo
Read more →ABCLAbCellera Announces Multi-Target Research Collaboration with Pfizer
VANCOUVER, British Columbia, Jan. 05, 2017 (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Pfizer Inc. (NYSE:PFE). AbCellera will apply its proprietary monoclonal antibody (mAb) screening platform to attempt to
Read more →ABCLAbCellera Completes Antibody Discovery Project With Kodiak Sciences to Identify Lead Therapeutic Candidates
VANCOUVER, British Columbia, Aug. 24, 2016 (GLOBE NEWSWIRE) -- AbCellera Biologics Inc., a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, announced today the successful completion of its antibody discovery partnership
Read more →ABCLAbCellera and MassBiologics Partner to Discover Fully Human Antibodies Against Drug-Resistant Bacteria
VANCOUVER, British Columbia, July 20, 2016 (GLOBE NEWSWIRE) -- AbCellera Biologics Inc., a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, today announced its third antibody discovery collaboration with MassBiologics o
Read more →ABCLAbCellera and Merck Sign Novel Therapeutic Antibody Discovery Collaboration
VANCOUVER, British Columbia, Jan. 27, 2016 (GLOBE NEWSWIRE) -- AbCellera, a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, today announced a new collaboration with Merck, known as MSD outside the United States and Can
Read more →ABCLAbCellera Announces Successful Completion of Collaboration for the Discovery of Fully Human Antibodies Against Pathogenic E. Coli and Ebola Virus
VANCOUVER, British Columbia, Jan. 20, 2016 (GLOBE NEWSWIRE) -- AbCellera announced today successful completion of its first antibody discovery partnership with MassBiologics of the University of Massachusetts Medical School. The project, funded by the Defense Advanced Research Pr
Read more →Competitive Position
How ABCL ranks across every disease it competes inCompetitive Position is a premium feature
See how ABCL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial